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Antibodies against a β-glucan-
protein complex of Candida 
albicans and its potential as 
indicator of protective immunity in 
candidemic patients
Antonella Torosantucci1, Mario Tumbarello2, Carla Bromuro1, Paola Chiani1, Brunella 
Posteraro3, Maurizio Sanguinetti4, Roberto Cauda2 & Antonio Cassone5
Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall 
β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although 
antibodies against each of the above components were detected in all subjects, candidemic patients 
had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and 
MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies 
found in candidemic patients were independent on the patient risk category, APACHE II score, presence 
of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, 
however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher 
titers in survivors than in non-survivors, particularly in those subject categories with the highest 
mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable 
of boosting anti-Candida immune responses upon infection, and some of these responses might be 
associated to the generation of protective immunity in patients with candidemia.
Candidemia is a remarkable health threat to hospitalized patients, including non-neutropenic subjects with 
advanced age and co-morbidities1–3. Despite progress in epidemiology, diagnosis and therapy, candidemia 
remains associated with high mortality (30–50%) and increasing incidence1, 3–7. In some hospital settings, 
Candida spp. are among the most frequent causes of bloodstream infections1, 8, 9.
While many risk factors which make a subject prone to develop the disease are known, and include deep sur-
gery and a number of invasive, medical-associated technologies, those influencing disease outcome are only par-
tially known and remain somewhat debated10. Data on causative Candida spp. and their antifungal resistance are 
widely available and suggest influence of local epidemiology on infection and possibly also on its outcome8, 11–14. 
A role for older age, inappropriate or non-timely antifungal therapy and general patient conditions on mortality 
rate appears to be plausible, though marked differences among the different studies have been reported5, 8, 13–16.
Only few studies have directly addressed the presence and magnitude of anti-Candida immunity, in particular 
antibody responses, in the above patients, mostly with the aim of providing diagnostic indicators17–24. We are 
studying antibody responses in candidemia with the main purpose of assessing whether and to what extent anti-
bodies to key structural and/or functional fungal antigens could be used as prognostic indicators and as a guide 
to identify new vaccine candidates. Following this research line, we have now focused on antibodies against a 
major polysaccharide-protein complex that is commonly present in Candida species causing candidemia. This 
complex contains both β1,3- and β1,6 glucans, of which the former is a currently accepted diagnostic marker of 
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candidemia and a molecular pattern recognized by a major receptor, Dectin-1, commonly expressed on cells of 
innate immunity25, 26. The complex also contains a β-glucan-associated mannoprotein, MP65, with a putative 
endo-glucanase activity which plays a critical role for cell wall growth and stability, and is a major target of 
anti-Candida adaptive immunity in humans27, 28.
Here we report that candidemic subjects are able to boost the anti-Candida response normally associated with 
colonization, and suggest that the capacity of boosting some of the above responses could indicate the generation 
of protective immunity, hence impact on disease outcome.
Results
Clinical and laboratory data. Seventy one candidemic patients (40 males and 31 females; mean age 
67.2 ± 3.1; median 72.0) and sixty nine age- and sex-matched control patients entered this study. All candidemic 
patients had Candida-positive blood cultures, positive β-glucanemia and signs and symptoms of the infection. 
For candidemic patients, the median duration of hospitalization and the APACHE II score at the time of the first 
positive blood culture were 21.5 days (range 2–180) and 16 (range 5–37), respectively. Thirty our subjects had 
a central venous catheter inserted. About half of the patients underwent previous surgery and for only seven of 
them there was evidence for immunosuppression. The vast majority of patients were treated with anidulafungin 
or caspofungin.
The controls were patients who were admitted to the hospital within the same period of time as the candi-
demic ones and were considered at risk for candidemia, but with Candida-negative blood-culture and negative 
β-glucanemia. Among them, 25 had a central venous catheter inserted, 30 had previous surgery, 6 were diabetics 
and 39 had previous antibiotic treatment. Other details are reported in the Supplementary Table 1.
Isolates from six Candida species were obtained from candidemic subjects, about 60% being C. albicans, alone 
or together with another species, followed by C. parapsilosis (19.7%), C. glabrata (7.0%), C. tropicalis (7.0%), 
and one isolate each of other minor Candida species. Of our patients, 31 (43.7%) did not survive. The mortality 
appeared to be associated with older age (P = 0.03), septic shock (P = 0.008), and diabetes mellitus (P = 0.008) but 
neither with APACHE II score, previous surgery, or other co-morbidities. The clinical data are detailed in Table 1.
Levels of serum anti-β-glucan or anti-MP65 IgG antibodies in candidemic patients. Presence 
and titers of anti-β-glucan and anti-MP65 antibodies at onset of candidemia were determined in sera from can-
didemic patients, taken at time of laboratory diagnosis of the first candidemia episode, and compared to those 
of non-candidemic controls. Both laminarin (β1,3-glucan) and pustulan (β1,6-glucan) were initially used as rep-
resentative of Candida β-glucan antigens. However, most candidemic patients showed high levels (≥500 pg/ml; 
Table 1) of circulating β1,3-glucan that could strongly bind the respective specific antibodies and make them 
poorly detectable in our ELISA test. In support of this interpretation, we found that our candidemic patients had 
significantly lower titers of anti-β1,3-glucan (laminarin) antibodies, as compared to the control group (Fig. 1A), 
and that their levels of anti-β1,3-glucan IgGs were inversely related to the amount of serum β1,3-glucan (Fig. 1B). 
In contrast, there was no significant correlation between β1,3-glucanemia and titers of anti-β1,6-glucan (pustu-
lan) IgGs (Fig. 1C). For this reason, only the anti-β1,6-glucan IgGs were further examined in this study as repre-
sentative of genuine titers of antibody against Candida β-glucan.
Figure 2 shows IgG titers against β1,6-glucan and MP65 in candidemic patients in comparison with the 
same antibodies in controls. The candidemic patients had higher IgG titers than controls against both MP65 
(P < 0.0001) and β1,6-glucan (P = 0.002). The ROC curves generated from these assays (Supplemental Figure S1) 
showed that titers of anti-MP65 IgGs could better discriminate candidemic from non-candidemic patients 
(AUC = 0.78, sensitivity 76 or 62% and specificity 59 or 90% at a cutoff of > 1200 or >2400, respectively) than 
those of anti-β1,6-glucan IgGs (AUC = 0.65, sensitivity 55 or 40% and specificity 52 or 40% at a cutoff of >4800 
or >9600, respectively).
The specificity of our anti-MP65 IgG ELISA was confirmed by qualitative western blot analyses of represent-
ative sera from candidemic and non-candidemic subjects using an anti-MP65 monoclonal antibody as positive 
control27. These assays clearly showed that the binding pattern of human sera substantially overlapped the one 
exhibited by the MP65-specific monoclonal antibody, with a reaction intensity in good apparent correlation with 
the anti-MP65 ELISA titers (Supplemental Figure S2).
The difference in the levels of anti-MP65 serum antibodies between candidemic and non-candidemic 
patients was significant both in patients infected by C. albicans (P < 0.0001 vs controls) and in those infected 
by non-albicans Candida species (P < 0.0001 vs controls, Fig. 3). The anti-MP65 IgG titers were overall similar 
(P > 0.05) in candidemic patients receiving or not receiving supportive steroids and with or without septic shock. 
However, the titers of anti-MP65 IgGs in diabetic patients with candidemia had the lowest levels over those in 
control population (geometric mean 1,467, 95% CI 685–3141 vs 726, 541–975; P = 0.37) compared to the titers in 
non-diabetic, candidemic patients (geometric mean 3,160, 95% CI 2,239–4,269; P < 0.0001). There was no statis-
tically significant correlation between β1,3-glucanemia values and anti-MP65 IgG titers, nor there was correlation 
between antibody levels and patient age or APACHE II score (data not shown).
Relationship between levels of anti-MP65 IgGs and survival of candidemic patients. We 
examined whether there was any association between survival of patients with candidemia and titers of 
anti-β1,6-glucan or anti-MP65 antibodies at candidemia diagnosis. As show in Fig. 4A, the survivors had over-
all higher antibody titers against both β1,6-glucan and MP65 as compared to the non-survivors. In the case of 
MP65 antigen, the higher titers of survivors were statistically significant, a finding particularly notable in patients 
with the highest mortality in our setting, as those of older age, or diabetic or with septic shock (Fig. 4B). In fact, 
logistic regression analysis showed a significant, positive relationship between values (logarithm) of anti-MP65 
titer and probability of survival, both in the whole population of candidemic patients (OR 2.61, Cl 95% 1.01–6.75, 
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p = 0.047) and in all three, high mortality-risk subpopulations (OR 17.7, Cl95% 1.10–284.8, p = 0.041 in dia-
betic patients; OR 4.38, Cl 95% 1.01–19.04, p = 0.048 in patients with septic shock; OR 3.78, Cl 95% 1.07–13.29, 
p = 0.038 in patients of age >65 years). No significant association between survival and anti-β1,6-glucan titers 
was instead found either in the whole population or in any category or sub-group of candidemic patients.
Discussion
In this study, we report novel observations about antibody responses against antigenic constituents of an immu-
nodominant polysaccharide-protein complex of the cell wall of Candida spp. in candidemic and non-candidemic, 
control patients. The saccharide antigens are the β1,3- and β1,6-glucan polymers which are known to be involved 
in many critical aspects of host-parasite relationship in candidiasis29, 30. The protein antigen is MP65, a putative 
All patients Survivors Non-survivors
P, survivors vs 
non-survivors
Odds ratio (95% 
confidence 
interval)
Candidemic patients, n (%) 71 40 (56.3) 31 (43.7)
Sex
Male, n/total (%) 40/71 (56.3) 22/40 (55.0) 18/40 (45.0) 0.81a 0.88 (0.34–2.27)
Female, n/total (%) 31/71 (43.7) 18/31 (58.1) 13/31 (41.9)
Age, median (range) 72 (14–91) 67.5 (20–86) 76 (14–91) 0.03b
Isolated Candida species, n/total (%)
C.albicans 38/71 (53.5) 21/40 (52.5) 17/31 (54.8)
C.parapsilosis 14/71 (19.7) 11/40 (27.5) 3/31 (9.7)
C.glabrata 5/71 (7.0) 2/40 (5.0) 3/31 (9.7)
C.tropicalis 5/71 (7.0) 2/40 (5.0) 3/31 (9.7) 1.0c 0.91 (0.35–2.33)
C.krusei 1/71 (1.4) 1/40 (2.5) 0/31 (0)
C.guilliermondii 1/71 (1.4) 0/40 (0) 1/31 (3.2)
C.lusitaniae 1/71 (1.4) 1/40 (2.5) 0/31 (0)
C.robusta 1/71 (1.4) 0/40 (0) 1/31 (3.2)
C.albicans associated with other 
Candida species 5/71 (7.0) 2/40 (5.0)* 3/31 (9.7)**
Antifungal treatmentd
Anidulafungin 34/71 (47.9) 16/40 (40.0) 18/31 (58.0)
Caspofungin 19/71 (26.8) 12/40 (30.0) 7/31 (22.6) 0.59e
Fluconazole 19/71 (26.8) 11/40 (27.5) 8/31 (25.8)
Liposomal Amphotericin B 9/71 (12.7) 6/40 (15.0) 3/31 (9.7)
Serum beta-glucan at the time of 
the first positive blood culture, 
median pg/ml (range)
>500 (97->500) >500 (97->500) >500 (135->500) 0.66b
Total duration of hospital stay at 
the time of the first positive blood 
culture, median days (range)
21.5 (2–180) 20 (2–71) 23 (3–180) 0.58b
Median (range) APACHE II score 
at the time of the fist positive blood 
culture
16 (5–37) 15 (5–35) 16 (5–37) 0.26b
Septic shock, n/total (%) 37/71 (52.1) 15/40 (37.5) 22/31 (80.0) 0.008a 4.07 (1.49–11.14)
Central venous catheter, n/total 
(%) 34/71 (47.8) 18/40 (45.0) 16/31 (51.6) 0.64
a 1.30 (0.50–3.33)
Previous surgery, n/total (%) 34/71 (47.8) 18/40 (45.0) 16/31 (51.6) 0.64a 1.30 (0.50–3.33)
Hematomalignancy, n/total (%) 5/71 (7.0) 2/40 (5.0) 3/31 (9.7) 0.65a 2.03 (0.32–13.01)
HIV, n/total (%) 1/71 (1.4) 0/40 (0) 1/31 (3.2) na na
Immunosuppressant, n/total (%) 7/71 (9.8) 5/40 (12.5) 2/31 (6.5) 0.46a 0.48 (0.09–2.68)
Steroids, n/total (%) 20/71 (28.1) 13/40 (32.5) 7/31 (22.6) 0.43a 0.61 (0.21–1.77)
Solid tumor, n/total (%) 16/71 (22.5) 8/40 (20.0) 8/31 (25.8) 0.58a 1.39 (0.46–4.25)
Chronic obstructive pulmonary 
disease, n/total (%) 20/71 (28.2) 11/40 (27.5) 9/31 (29.0) 1.00
a 1.08 (0.38–3.05)
Chronic renal failure, n/total (%) 13/71 (18.3) 8/40 (20.0) 5/31 (16.1) 0.76a 0.77 (0.22–2.64)
Diabetes mellitus, n/total (%) 16/71 (22.5) 4/40 (10.0) 12/31 (38.7) 0.008a 5.68 (1.61–20.06)
Previous antibiotic treatment (30 
days), n/total (%) 54/71 (76.1) 32/40 (80.0) 22/31 (70.9) 0.41
a 0.61 (0.20–1.83)
Table 1. Demographic, clinical and microbiological data of candidemic patients considered in the study. 
aFisher exact test; bMann-Whitney U test; *C.albicans + C.krusei (1), C.albicans + C.guilliermondii (1);  
**C.albicans + C.glabrata cFisher exact test evaluating isolation of non-albicans species, alone or in association, 
vs the isolation of C.albicans only dNine patients were treated with more than one antifungal eChi-square test 
na = not applicable.
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Figure 1. Serum titers of anti-β1,3-glucan IgG are lower in candidemic patients than in controls, and are 
inversely correlated to levels of circulating β1,3-glucan. Panel a: Individual, anti-β1,3-glucan IgG titers in 
patients with candidemia (n = 71) and in non-candidemic controls (n = 69). A single serum samples was 
analyzed for each subject. For candidemic patients, sera were those obtained at onset of candidemia, i.e. 
from the same blood specimen of the first Candida-positive blood culture. Geometric means are indicated 
by the lines. P was estimated by the Mann-Whitney U test. Panels b and c: Correlation between serum titers 
of anti-β1,3-glucan (b) or anti-β1,6-glucan (c) IgG and beta-glucanemia in candidemic patients. Correlation 
coefficients rs and P values were calculated by the Spearman’s rank correlation analysis.
Figure 2. Onset of candidemia is associated to a significant rise of anti-MP65 and anti-β1,6-glucan antibodies. 
The graph shows the individual titers of anti-MP65 (Panel a) or anti-β1,6-glucan IgGs (Panel b) measured in 
control (n = 69) and candidemic patients (n = 71). Sera of candidemic subjects (one for patient) were from the 
same blood specimen of the first Candida-positive blood culture. Lines are at geometrical mean titers. P values 
were calculated by the Mann-Whitney U test.
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endo-glucanase enzyme, usually found associated to β1,3-glucan, and previously identified as a major target of 
T cell responses to C. albicans27, 28. Both β-glucans and MP65 have been shown to be expressed and abundantly 
secreted by yeast and hyphal cells of C.albicans in which they play an essential physiological role for cell wall 
growth and pathogenesis, including adherence to host cells and biofilm formation28, 30. Less is known regarding 
these antigens in other pathogenic Candida spp., where, however, they are present31 and possibly play similar 
roles as in C. albicans. Because of their strong involvement in the fungal biology and immune response, we con-
sidered of special relevance to assess the antibody response to these constituents in candidemic subjects. In fact, 
few studies have addressed antibody responses in candidemic subjects, mostly for diagnostic purposes17–24, and 
none of them specifically investigated the antibodies to the β-glucan complex of Candida cell wall. A report by 
Pitarch and coworkers describing a C. albicans immune serological proteome23 showed that candidemic subjects 
have serum antibodies against a high number of fungus proteins and their peptide sequences, most of which were 
poorly or not represented at all in non-candidemic subjects. Other authors have recently reported on the pres-
ence in candidemic subjects of dominant antibodies against proteins secreted during yeast to hypha transition 
of C. albicans and highlighted the importance of the glycosylated moieties of these proteins as target of antibody 
responses19. Overall, non-immunocompromised candidemic patients are evidently able to raise anti-Candida 
Figure 3. Levels of anti-MP65 IgGs are comparably increased in patients infected by C. albicans or by other, 
non-albicans, Candida species. The plot compares the distribution of anti-MP65 IgG titers in patients with C. 
albicans candidemia (n = 43), patients infected by other Candida species (n = 28) and non-candidemic controls 
(n = 69). Bottom and top of the box represent the first and third quartiles, respectively. Line inside the box is the 
median titer and whisker show minimum and maximum values. P was calculated by Kruskal-Wallis ANOVA 
and Dunn’s post-test.
Figure 4. Comparison of anti-MP65 and anti-β1,6-glucan antibody levels at candidemia diagnosis in survivors 
and non-survivors among candidemic patients. Panel a: Distribution of individual IgG titers against MP65 or 
β1,6 glucan in survivors (n = 40) and non-survivors (n = 31). Panel b: Levels of anti-MP65 IgGs in surviving 
and non-surviving candidemic patients belonging to categories of high mortality risk in our setting (patients 
aged >65 years, with septic shock or with diabetes mellitus, n survivors vs n non-survivors = 22 vs 25, 15 vs 22 
and 4 vs 12, respectively) Logistic regression analysis was used to calculate the Odds ratio for the relationship 
between survival and anti-MP65 and anti–β1,6-glucan antibody titers.
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responses during the infection, some of which have also been assumed to be of diagnostic relevance21, 22, 24, 25. 
Here we report that candidemic patients, at the time of candidemia diagnosis, had significantly higher titers of 
anti-MP65 and anti-β1,6-glucan antibodies than non-candidemic subjects. The higher anti-MP65 titers of candi-
demic patients were not restricted to those infected by C. albicans, corroborating the notion that this important 
antigen is fully expressed also in other pathogenic species of Candida31.
It is known that C. albicans colonization of mucosal surfaces, in particular the GI tract, and skin of most 
healthy subjects induces strong humoral and cellular responses32. The antibody levels against the β1,6-glucan 
moiety of the glucan/MP65 complex in non-candidemic, but likely Candida-colonized subjects, were in the same 
range of those previously reported in normal healthy subjects29. Hence, the elevated titers of these antibodies in 
candidemic patients (reasonably including those againstMP65) are most likely due to a booster of anti-Candida 
immune response to fungus invasion, that is expected in a generally non-immunocompromised patient popu-
lation. Actually, the above booster was seen in all categories of candidemic patients irrespective of their age, sex, 
performance, antifungal treatment and co-morbidity (with the possible exception of diabetic patients; see below) 
and occurred against both the polysaccharide and, particularly high, against the protein antigen.
Despite the existence of protective anti-Candida antibodies, amply documented in experimental studies33–35, 
very little is known about the existence and impact of such antibodies in clinical setting. The large majority of the 
studies done so far have addressed the diagnostic, rather than the prognostic, role of anti-Candida antibodies. 
Here we examined whether there was any association between levels of anti-β1,6-glucan or anti-MP65 antibod-
ies and disease outcome in our candidemia setting. Overall, our data show a statistically significant association 
between survival and antibody responses against the MP65, but not against the β1,6-glucan, antigen in the whole 
candidemia population, with the expected particular strength when anti- MP65 antibody titers and survival were 
correlated in the categories of candidemic subjects where most of the mortality is observed (older age, diabet-
ics, septic shock patients). Notably, the anti-MP65 titers of the diabetic, non-survivors were very close to those 
of non-candidemic subjects, suggesting for the inability of these patients to boost a substantial anti-Candida 
response following infection.
These data do not allow to conclude that MP65 is a protective antigen in candidemia, since it could only be 
an indirect marker of immune response, even of non-antibody type, against MP65 itself and/or other antigens. 
Bloodstream infection and sepsis is expected to cause some immune dysregulation at least in those categories 
of candidemic subjects heavily invaded by the fungus. Disorders in T cell and pro-inflammatory cytokines have 
indeed been reported that could, in some subjects, interfere with the booster of antibody responses17, 36. In particu-
lar, patients with Candida sepsis have been reported to show a suppressive immune-phenotype including T cell 
exhaustion and decreased expression of co-stimulatory molecules in CD4+ T cells36. It is therefore conceivable that 
in some candidemic subjects the CD4+ T cells are unable to express their full helper potential for antibody produc-
tion. Our observation that the anti-MP65 but not the anti-β1,6-glucan antibodies had lower titers in non-survivors 
is in accord with the above hypothesis, being MP65 and β1,6-glucan, respectively, a T-helper-dependent and 
-independent antigen. Whichever the interpretation, our data suggest that the subjects unable to mount a more 
intense or more specific anti-Candida immunity following infection could have a worse outcome.
Our study has the well-known limitations of a retrospective one, and reporting only from a single, though 
large, clinical center. Some categories of subjects with high proneness to candidemia and its associated mortality 
(e.g. diabetics) were scarcely represented among both patients and controls. In addition, the non-candidemic, 
control patients were not perfectly matched for some morbidities to the candidemic patients, although belong-
ing to the same at risk categories and largely sharing the same predisposing factor Overall, our suggestion that 
the capacity to boost anti-Candida immunity following infection might have an impact on candidemia sur-
vival, though being statistically supported, remains highly speculative and, as such, should be taken cautiously. 
Nonetheless, our data invite to consider further prospective and possibly multicenter studies to assess whether 
antibody measurements against properly selected fungal antigens could help identify candidemic subjects with 
differential survival potential. These studies could suggest ways of harnessing immune responses to the infectious 
fungi in some categories of candidemic subjects by appropriate immune-stimulation (including vaccination) in 
order to improve the prognosis in a clinical setting characterized by particularly high mortality.
Methods
Study population and design. We included in the study patients with culture-proven candidemia who 
were hospitalized during the period from January 2012 to February 2016 at the A. Gemelli Hospital of Rome, 
Italy, which is an academic tertiary care center with 1,400 beds and ~50,000 hospital admissions per year. Patients 
were identified by electronically querying the clinical microbiology laboratory database, and were included only if 
complete data series could be retrieved from their medical charts and from laboratory databases, including demo-
graphics (age, sex), comorbid conditions (diabetes mellitus, chronic obstructive pulmonary disease, chronic renal 
failure, solid organ cancer, hematologic malignancy, human immunodeficiency virus [HIV] infection), insertion 
of a central venous or urinary catheter, use of immunosuppressive agents, surgery, exposure to antibiotics within 
30 days of the onset of candidemia, risk days (i.e., number of hospital days from admission to the date of the 
first positive blood culture, antifungal therapy, and hospital mortality [the last defined as death within 30 days 
of the first documented candidemia episode]). The local institutional review committee approved the study, and 
informed consent was waived because of the observational, retrospective nature of the investigation. All patient 
samples and data records were rendered anonymous before performing any experimental or statistical analyses.
Diagnosis of candidemia was made on the basis of ≥1 blood cultures growing Candida species and on the 
presence of signs and symptoms of infection. Only the first episode of candidemia was reported for patients with 
recurrent or subsequent episodes of infection. In addition, only patients with β1,3-glucanemia assay results (see 
below) were included.
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Controls were age- and sex-matched patients who were admitted to the hospital within the same time interval 
as the candidemic ones, and were considered at risk for candidemia but with Candida-negative blood-culture and 
negative β-glucanemia. Only candidemic and non-candidemic patients whose serum was available in suitable 
quantity and quality for performing immunoassays were considered.
Microbiological assays. Blood cultures were obtained as part of normal clinical practice and processed 
using a Bactec (BD Diagnostic Systems, Sparks, MD) or BacT/Alert (bioMérieux, Marcy l’Etoile, France) system. 
After sub-culturing on Difco Candida bromocresol green (BCG) agar medium, yeast isolates were identified to 
the species level by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrome-
try37. Sera from blood specimens of candidemic and non-candidemic controls, as described in the previous sec-
tion, were tested for β1,3-D-glucan (BDG; Fungitell; Associates of Cape Cod Inc., Falmouth¸ MA) as previously 
described38. The concentration of BDG in each sample was automatically measured within a range from 31.25 to 
500 pg/ml. Using the BDG cutoffs proposed by the manufacturer, we considered a BDG to be positive if the value 
was ≥80 pg/ml and negative if the value was <80 pg/ml.
Immunological assays. Laminarin (essentially a beta-1,3-linked glucan with occasional beta-1,6-linked 
side chains of a single glucose residue) and pustulan (a linear, beta-1,6-linked glucan) were used as model antigens 
representing β1,3- and β1,6- Candida glucans, respectively29. They were purchased from Sigma Chem. Co. (St. 
Louis, MO) and Calbiochem (La Jolla, CA), respectively. Full length, poly-histidine tagged, recombinant MP65 
protein was produced in E.coli by GenScript (Piscataway, NJ) and purified to homogeneity by nickel-affinity 
chromatography.
Sera of candidemic patients and non-candidemic controls, were extracted from the serum bank of the A. 
Gemelli Hospital microbiology laboratory. A single serum sample was analyzed for each subject under study. For 
candidemic patients, serum samples were those corresponding to laboratory diagnosis of the first candidemia 
episode (i.e., obtained from the same blood specimen of the first Candida-positive blood culture and found pos-
itive for presence of circulating β1,3-glucan). All sera were heated at 56 °C for 30 min and stored individually at 
−80 °C.
Immunoglobulin G (IgG) titers against the β-glucans and MP65 antigens were determined by ELISA, essen-
tially as already described29. Briefly, polystyrene microtiter plates (MaxiSorp; NUNC, Roskilde, Denmark) 
coated with the antigens (50 µg/ml polysaccharide or 0.5 µg/ml MP65 in 0.05 M carbonate buffer, pH 9.6, 100 µl/
well, overnight at + 4 C) and blocked 2 h at 37 °C with Blocker TM Casein in PBS (Thermo Scientific, Rockford, 
IL, USA), were reacted with twofold dilutions of the human sera in blocking solution, followed by alkaline 
phosphatase-conjugated, gamma chain-specific, goat anti-human IgG (Sigma). Plates were developed 30 min with 
p-nitrophenyl phosphate disodium (Sigma) as the enzyme substrate and read for absorbance at 405 nm. Readings 
from negative control wells (wells without antigen) were subtracted from all absorbance values. Antibody titers 
were defined as the reciprocal of the highest dilution of sera that gave an optical density at least twice that of the 
correspondent negative control.
For western blot analyses, the MP65 protein preparation (2.5 µg/lane) was separated by SDS-PAGE in 5 to 
15% polyacrylamide slab gels (Bio-Rad, Hercules, CA) and transferred onto nitrocellulose (0.2-mm pore size), 
as previously described27. After blocking of the nitrocellulose sheets for 2 h at room temperature with Blocker 
TM Casein in PBS (Thermo Scientific), the transferred protein was reacted for 1 h at 37 °C with control or patient 
sera (diluted 1:200 in Blocker TM Casein in PBS) or with a murine, anti-MP65 monoclonal IgG (7H627, 5 µg/
ml in the same diluent of human sera). Sheets were extensively washed with PBS and incubated with alkaline 
phosphatase-conjugated, anti-human or anti-mouse IgG antibodies, as appropriate. Reactive bands were devel-
oped with the nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate reagent (Sigma).
Statistics. Categorical variables were compared using the Fisher’s exact test or the Chi-square test. 
Comparison of continuous data among groups were performed with the Mann-Whitney U-test, confirmed by 
the Student’s t test, whereas one-way ANOVA or Kruskal-Wallis test followed by Bonferroni’s or Dunn’s post-tests, 
respectively, were used for multiple comparisons. Receiver-operator characteristics (ROC) curves were con-
structed to evaluate the potential of analyzed antibodies for an accurate discrimination between candidemic 
and non-candidemic patients. Spearman’s rank correlation coefficient was calculated to assess the relationships 
between the different variables in patients. A p value < 0.05 was accepted as statistically significant. All tests were 
performed with the GraphPad Prism software, version 4.00 (GraphPad, San Diego CA). Relationship between 
survival and logarithm to base 10 of anti-MP65 and anti-β1,6-glucan antibody titers in all candidemic patients 
and in patient subgroups was assessed by logistic regression analyses by the SPSS v19 software.
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